APLM Stock Forecast 2025-2026
Distance to APLM Price Targets
APLM Price Momentum
10 Quality Stocks Worth Considering Now
Researching Apollomics (APLM) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on APLM and similar high-potential opportunities.
Latest APLM Stock Price Targets & Analyst Predictions
APLM has shown a year-to-date change of -39.0% and a 1-year change of -87.4%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for APLM. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
APLM Analyst Ratings
APLM Price Target Range
Latest APLM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for APLM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 8, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $2.00 |
| Apr 1, 2024 | EF Hutton | Michael King | Buy | Maintains | $6.50 |
| Apr 1, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $5.00 |
| Nov 20, 2023 | HC Wainwright & Co. | Buy | Reiterates | $17.00 | |
| Oct 3, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $17.00 |
| Aug 23, 2023 | EF Hutton | Michael King | Buy | Assumes | $25.00 |
| Jun 5, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $18.00 |
| Jun 1, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Initiates | $18.00 |
| May 25, 2023 | EF Hutton | Michael King | Buy | Assumes | $25.00 |
| Apr 25, 2023 | EF Hutton | Michael King | Buy | Initiates | $25.00 |
Apolomics Inc. (APLM) Competitors
The following stocks are similar to Apollomics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Apolomics Inc. (APLM) Financial Data
Apolomics Inc. has a market capitalization of $6.56M with a P/E ratio of 0.0x. The company generates $198,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of +1,007.4% and return on equity of -233.7%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Apolomics Inc. (APLM) Business Model
About Apolomics Inc.
Develops cell and gene therapies for cancer.
Apolomics Inc. operates by innovating in the oncology sector through the development of advanced cell and gene therapies. The company generates revenue by creating novel therapeutic solutions, such as immuno-oncology and oncogene targeting therapies, and through collaborations with scientific institutions that enhance its research capabilities.
Headquartered in the United States, Apolomics Inc. is committed to leveraging cutting-edge biotechnology to provide precision medicine tailored to specific cancer targets. The company's focus on research and development positions it as a significant player in the healthcare industry, aiming to expand treatment options and make impactful contributions to cancer therapy.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
13
CEO
Dr. Guo-Liang Yu Ph.D.
Country
United States
IPO Year
2021
Website
www.apollomicsinc.comApolomics Inc. (APLM) Latest News & Analysis
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
16 days agoApollomics Inc. (Nasdaq: APLM) reported its fiscal year 2024 financial results and provided updates on its oncology drug candidates aimed at challenging cancers.
Apollomics' financial results and clinical updates indicate its progress in oncology, impacting potential revenue and market confidence, which can influence stock performance.
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
19 days agoApollomics Inc. has partnered with LaunXP to develop and commercialize its c-Met inhibitor, vebreltinib, combined with an EGFR inhibitor for NSCLC treatment in Asia (excluding China, HK, Macau).
The partnership enhances Apollomics' market reach in Asia for its promising cancer treatment, potentially boosting revenue and investor confidence in the company's growth prospects.
Apollomics Inc. reported that its Phase 3 trial of uproleselan for relapsed or refractory acute myeloid leukemia in China did not show favorable results.
The unfavorable results from Apollomics' Phase 3 trial may lead to decreased investor confidence, potential stock price decline, and concerns over the company's future in oncology drug development.
Apollomics Inc. has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, allowing its Class A ordinary shares to continue listing on the Nasdaq Capital Market.
Apollomics regaining compliance with Nasdaq's minimum bid price requirement signals financial stability and supports its continued market presence, potentially boosting investor confidence and share value.
Apollomics Inc. (Nasdaq: APLM) will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, focusing on its oncology drug candidates.
Apollomics' presentation at a major investment conference signals potential visibility and interest in its oncology drug candidates, influencing investor sentiment and stock performance.
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
8 months agoApollomics Inc. (Nasdaq: APLM) reported its financial results for H1 2024 and provided updates on its oncology drug pipeline targeting challenging cancers.
Apollomics' financial results and pipeline updates signal its progress in oncology, which can impact stock performance and investor confidence in its future prospects.
Frequently Asked Questions About APLM Stock
What is Apolomics Inc.'s (APLM) stock forecast for 2025?
Analyst forecasts for Apolomics Inc. (APLM) are not currently available. The stock is trading at $5.95.
Is APLM stock a good investment in 2025?
Analyst ratings for APLM are not currently available. The stock is currently trading at $5.95. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for APLM stock?
Price predictions from Wall Street analysts for APLM are not currently available. The stock is trading at $5.95.
What is Apolomics Inc.'s business model?
Apolomics Inc. operates by innovating in the oncology sector through the development of advanced cell and gene therapies. The company generates revenue by creating novel therapeutic solutions, such as immuno-oncology and oncogene targeting therapies, and through collaborations with scientific institutions that enhance its research capabilities.
What is the highest forecasted price for APLM Apolomics Inc.?
Price targets from Wall Street analysts for APLM are not currently available. The stock is trading at $5.95.
What is the lowest forecasted price for APLM Apolomics Inc.?
Price targets from Wall Street analysts for APLM are not currently available. The stock is trading at $5.95.
What is the overall APLM consensus from analysts for Apolomics Inc.?
Analyst ratings for APLM are not currently available. The stock is trading at $5.95.
How accurate are APLM stock price projections?
Stock price projections, including those for Apolomics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.